ARCHIVES

FDA Committee Can’t Find “Reasonable” Evidence Alkylating Agent Clinical Use Is Carcinogenic

This article is from The Cancer Letter archive.

Vol. 02 No. 37 | September 10, 1976

Download PDF Visit The Full Archive

Related Articles

Cooperative Groups, NCI To Talk About Overlaps

March 14, 1975

Cytogen Corp.’s Imaging Agent ProstaScint Added to NCCN Prostate Cancer Guidelines.

March 31, 2000

In Brief: Krakoff moves To Scotland; Salmon Wins Waldenstrom Award; ONS endorses Reform

November 5, 1993

HHS Says NIH Improperly Used Program For Scientists To Hire Administrators.

July 13, 2001

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

November 1, 1985

Oregon Center Launching $1 Billion Program To Identify Lethal Cancers Before They Kill

May 9, 2014